Evidence map›Paper›PMID 41799499›Full record

ArticleOncology research2026

Prognostic Significance of DNA Repair Gene mRNA Expression in Early-Stage Breast Cancer: Insights into Clinical Relevance.

Ina Shehaj, Slavomir Krajnak, Katrin Almstedt, Yaman Degirmenci, Roxana Schwab, Kathrin Stewen, Walburgis Brenner, Annette Hasenburg, Marcus Schmidt, Anne-Sophie Heimes

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ina ShehajDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Slavomir KrajnakDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Katrin AlmstedtDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Yaman DegirmenciDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Roxana SchwabDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Kathrin StewenDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Walburgis BrennerDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Annette HasenburgDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Marcus SchmidtDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.
Anne-Sophie HeimesDepartment of Obstetrics and Gynecology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, 55131, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prognostic and therapeutic roles of biological markers in early-stage breast cancer (eBC) warrant further investigation. Non-Breast Cancer (BRCA) genes, along with moderate- and low-penetrance breast cancer risk variant genes, are crucial for maintaining genome stability, yet their prognostic significance in eBC remains unclear. This study aimed to evaluate the impact of non-BRCA genes on clinical outcomes in eBC patients. Significant correlations were observed between the messenger ribonucleic acid (mRNA) expression levels of the genes Background: The prognostic significance of various biological and non-BRCA genetic in early-stage breast cancer (eBC) remains unclear and warrants further investigation. This study therefore aimed to evaluate the prognostic impact of these genes on clinical outcomes in breast cancer. Methods: Patients included in this study were subdivided into two groups based on low and high messenger ribonucleic acid (mRNA) expression levels. Statistical analysis, including Kaplan-Meier curves, univariable, and multivariable Cox regression analyses, was performed to assess metastasis-free survival (MFS) of mRNA expression of non-BRCA genes. Subgroup analyses were also conducted among four different molecular subtypes of eBC. Results: Our analysis revealed significant correlations between mRNA-expression levels of Conclusions: This study underscores the prognostic significance of moderate penetrance breast cancer risk variant genes, such as

Indexed as

Biomarkers, TumorBreast NeoplasmsDNA RepairRNA, MessengerAdultAgedAtaxia Telangiectasia Mutated ProteinsFemaleGene Expression Regulation, NeoplasticHumansMiddle AgedNeoplasm StagingPrognosisRecQ HelicasesAtaxia Telangiectasia Mutated ProteinsATM protein, humanBiomarkers, TumorBloom syndrome proteinRecQ HelicasesRNA, MessengerAtaxia-telangiectasia mutated (ATM)Bloom helicase gene (BLM)breast cancer (BC)gene expression analysessurvivalWRN RecQ Like Helicase (WRN)

Identifiers

PMID41799499
PMCPMC12963681

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.